Daxor CEO to Present at iAccess Virtual Investment Conference
Event summary
- Daxor CEO Michael Feldschuh to present at iAccess Virtual Alpha Best Ideas Spring Investment Conference on March 10, 2026, at 2:00 PM ET.
- Feldschuh will also conduct one-on-one meetings with institutional investors on March 11, 2026.
- Daxor focuses on blood volume measurement technology, addressing a 'multi-billion-dollar silent crisis' in healthcare.
- Company operates a 20,000-square-foot U.S.-based manufacturing facility and is ISO certified.
The big picture
Daxor's participation in the iAccess conference underscores its push to increase market and physician acceptance of its Blood Volume Analysis (BVA) diagnostic. The company's focus on precise blood volume measurement addresses a critical gap in high-cost medical conditions like heart failure, positioning it in the growing value-based healthcare sector. The event provides a platform to showcase its technology to institutional investors, potentially accelerating its market expansion.
What we're watching
- Market Expansion
- The pace at which Daxor can scale its blood volume measurement technology in the value-based healthcare market.
- Investor Sentiment
- How the presentation and one-on-one meetings will impact institutional investor interest and potential partnerships.
- Regulatory Compliance
- Whether Daxor can maintain FDA clearance and ISO certification while expanding its distribution channels.